Maze Therapeutics, Inc. (MAZE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $31.73
- As of
Kresmion compiles this page from MAZE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Maze Therapeutics, Inc. (MAZE): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-16.
See the full MAZE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MAZE on one page. Preview it with sample data, then open it live with a free account.
Preview the MAZE dossierActive events for MAZE
- high13F: large reduction
CITADEL ADVISORS LLC cut 98% of MAZE (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 97% of MAZE (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +90% to MAZE (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 74% of MAZE (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +1118% to MAZE (2026Q2)
FREE, NO ACCOUNT
Every event on MAZE, as it fires
You are seeing 5 of 11 events recorded on MAZE since 2026-06-04.
The five above all landed on 2026-08-16. The other 6 were recorded on 2 other days. 7 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MAZE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 578784100 · 2026Q2 | $25.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 578784100 · 2026Q2 | $5.8M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 578784100 · 2026Q2 | $359K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MAZE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MAZE against its peers
MAZE's operating margin of -85.3% ranks in the 46th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | MAZE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 168M USD | 110M USD | 54 | 13 |
| Gross margin | n/a | 91.5% | n/a | 6 |
| Operating margin | -85.3% | -79.5% | 46 | 13 |
| Net margin | -78.3% | -112.6% | 57 | 14 |
| Return on equity | -36.9% | -59.0% | 63 | 14 |
Peers (19): MESO, QURE, NBTX, STOK, NVAX, CMPS, RARE, IMCR, NTLA, ZBIO, URGN, MLYS, FBRX.D, VIR, ABSI, SRPT, SLS, REPL, ANAB. Left out: KLRA (no annual filing), COAG (no annual filing), TRAX (no annual filing), BRVE (no annual filing), GENB (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (MAZE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MAZE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MAZE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.